A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

Sara M. Tolaney,Kevin Kalinsky,Virginia G. Kaklamani,D. R. DAdamo,Gursel Aktan,Michaela L. Tsai,Ruth ORegan,Peter A. Kaufman,S Wilks,Eleni Andreopoulou,Debra A. Patt,Yuan Yuan,Grace Wang,D Xing,Ella Kleynerman,Vassiliki Karantza,Sami Diab

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

2020

Sara M. Tolaney
Kevin Kalinsky
Virginia G. Kaklamani
D. R. DAdamo
Gursel Aktan
Michaela L. Tsai
Ruth ORegan
Peter A. Kaufman
S Wilks
Eleni Andreopoulou
Debra A. Patt
Yuan Yuan
Grace Wang
D Xing
Ella Kleynerman
Vassiliki Karantza
Sami Diab

1015Background: As monotherapies, both ERI (a chemotherapeutic microtubule inhibitor) and PEMBRO (a programmed death [PD]-1 blocking immunotherapy) have shown promising antitumor activity in mTNBC....

Keywords:

Oncology
Triple-negative breast cancer
Internal medicine
Pembrolizumab
Eribulin
Pathology
Medicine
programmed death
antitumor activity
Immunotherapy
Microtubule Inhibitor
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations